Navigation Links
Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Date:12/10/2007

therapy.

Genta has filed a currently pending appeal to the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), which seeks reconsideration of FDA's decision in December 2006 not to approve the use of Genasense in patients with relapsed/refractory CLL.

"The addition of Genasense to chemotherapy has resulted in a clinically meaningful survival benefit for patients who achieved CR," commented Dr. O'Brien. "These data strongly confirm the high degree of clinical benefit that accrues to patients who achieve CR. Achievement of CR remains an essential goal of CLL treatment."

"As one of the patients who remains in CR more than 4 years after receiving Genasense on this study, I strongly support the pending appeal of FDA's decision that declined to make this drug available to other patients who suffer from CLL," commented Thomas F. Mahoney, who entered the Phase 3 Genasense trial in 2002.

Genasense in CLL

In the Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study - the only randomized controlled trial ever conducted in this population - achieved its intent-to-treat primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. In addition, the duration of CR - a prospectively specified and independent secondary endpoint -- was also significantly longer for patients treated with Genasense (median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for patients treated with chemotherapy alone).

The data presented today are exploratory analyses based on extended follow-up of all pat
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets  has announced the addition ... Separation Columns Market" report to their offering. ... two enantiomers of the same compound with different affinities ... thus possessing different elution times. Chiral stationary phases are ... The chiral separation chromatography columns market is growing at ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Casen Buswell has ... and muscles to harden.  His case is one of only ... the world.  The only hospital in the United ... the world, offering treatment with the dual wave-length laser, is ... San Antonio . Using a laser available in ...
(Date:9/18/2014)... YORK , Sept. 18, 2014 This BCC Research ... share of major players, market growth and size, and opportunities ... trends and revenue through 2018. Patent analysis in the report ... as the U.S., Europe and ... to: - Define and discuss the global medical device technologies ...
Breaking Medicine Technology:Micro Market Monitor: Global Chiral Separation Columns Market 2Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4
(Date:9/19/2014)... Capital Region Periodontics and Dental Implants, led ... the latest addition to their treatment options for ... dental implants. Often referred to as the “gentle ... factor normally associated with traditional gum surgery. No ... this procedure a very attractive oral surgery alternative ...
(Date:9/19/2014)... wonder material graphene has been used to detect molecules ... , The biosensor has been shown to be more ... in use, and was able to provide results in ... a rapid, point-of-care diagnostic tool for patients. , The ... Publishing,s journal 2D Materials . , To develop ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... a traditional Scandinavian style of eating, is ... Much like Diet Doc’s medical weight ... cooking and eating good food which leads ... focuses on teaching patients to understand how ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Activz Whole-Food ... Greens Smoothie product, a new whole-food produce powder ... in Baltimore, MD. Activz Greens Smoothie is ... in one convenient – and absolutely delicious —Greens Smoothie. ... in Baltimore, MD. , The new ...
(Date:9/19/2014)... QUT Centre for Accident Research & Road Safety - ... Safety in Transport Conference (OSIT) which is being held ... Ross Blackman, a CARRS-Q road safety researcher, said speed ... speed limits and related traffic controls remained in place ... wolf. If people are asked to slow down at ...
Breaking Medicine News(10 mins):Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Graphene sensor tracks down cancer biomarkers 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2
... new bladder cancer therapy show promising interim results. Lead ... drug Urocidin follows thirty years of his research in ... results of the trial," says Dr. Morales, professor emeritus ... director of the Queen,s University Centre for Applied Urological ...
... crashes each year. As a result, most states have put laws ... cell phones and PDAs while driving. But a new study led ... distracted driving and the laws being passed to address the problem. ... Journal of Preventive Medicine , is the first comprehensive collection and ...
... improve their outcomes if they walk briskly for at least ... recent study in Cancer Research , a journal of ... that men who walk briskly after their diagnosis may delay ... Erin Richman, Sc.D., a research associate at the University of ...
... MA May 24, 2010 CardioCareLive, the world,s ... Johns Hopkins University School of Medicine, today announced ... to be held over two days on Tuesday ... of interest to cardiovascular care and internal medicine ...
... 24, 2011 The latest episode in the ... Global Challenges/Chemistry Solutions ," focuses on new blood ... infected with an antibiotic-resistant bacterium that,s become a ... "superbug" is called methicillin-resistant Staphylococcus aureus, or simply ...
... , TUESDAY, May 24 (HealthDay News) -- Rain-making bacteria ... particles play in the Earth,s precipitation cycle, new research ... at the general meeting of the American Society for ... within the center of hailstones, suggesting that airborne microorganisms ...
Cached Medicine News:Health News:New made-in-Canada therapy for bladder cancer shows promising results 2Health News:Temple-led study finds widening gap between distracted driving and legislation 2Health News:Brisk walking could improve prostate cancer outcomes 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 2Health News:CME on atrial fibrillation, interventional cardiology and lipids online at CardioCareLive 3Health News:New American Chemical Society podcast: Fast test to diagnose MRSA infections 2Health News:Airborne Germs May Spur Rain, Snow, Hail 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: